ArticleOpen forum infectious diseases2023

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.

Jaynier Moya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.